Conflict of interest as seen from a researcher’s perspective
Abstract The continuous growth of the pharmaceutical industry is expected to require a considerable output of new drugs, with speedy development and approval processes. This profit-driven expansion of the drug market may broaden the already established erosion of the role of academia in favor of com...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Schieppati, Arrigo [verfasserIn] |
|---|
| Format: |
Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2002 |
|---|
| Schlagwörter: |
|---|
| Anmerkung: |
© Opragen Publications 2002 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Science and engineering ethics - Kluwer Academic Publishers, 1995, 8(2002), 3 vom: Sept., Seite 337-342 |
|---|---|
| Übergeordnetes Werk: |
volume:8 ; year:2002 ; number:3 ; month:09 ; pages:337-342 |
| Links: |
|---|
| DOI / URN: |
10.1007/s11948-002-0053-y |
|---|
| Katalog-ID: |
OLC2029167657 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2029167657 | ||
| 003 | DE-627 | ||
| 005 | 20230508184824.0 | ||
| 007 | tu | ||
| 008 | 200819s2002 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11948-002-0053-y |2 doi | |
| 035 | |a (DE-627)OLC2029167657 | ||
| 035 | |a (DE-He213)s11948-002-0053-y-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 100 |a 500 |q VZ |
| 084 | |a 19,2 |2 ssgn | ||
| 100 | 1 | |a Schieppati, Arrigo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Conflict of interest as seen from a researcher’s perspective |
| 264 | 1 | |c 2002 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © Opragen Publications 2002 | ||
| 520 | |a Abstract The continuous growth of the pharmaceutical industry is expected to require a considerable output of new drugs, with speedy development and approval processes. This profit-driven expansion of the drug market may broaden the already established erosion of the role of academia in favor of commercial clinical research organizations. Less and less control on the clinical trial design, its conduct and the resulting publication[s] is the likely consequence. Academic medicine and governments should find means to sustain the development of independent clinical research. | ||
| 650 | 4 | |a conflict of interest | |
| 650 | 4 | |a academic research | |
| 650 | 4 | |a drug development and research | |
| 650 | 4 | |a clinical trial design | |
| 700 | 1 | |a Perico, Norberto |4 aut | |
| 700 | 1 | |a Remuzzi, Giuseppe |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Science and engineering ethics |d Kluwer Academic Publishers, 1995 |g 8(2002), 3 vom: Sept., Seite 337-342 |w (DE-627)19230397X |w (DE-600)1304534-9 |w (DE-576)051378167 |x 1353-3452 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2002 |g number:3 |g month:09 |g pages:337-342 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s11948-002-0053-y |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-TEC | ||
| 912 | |a SSG-OLC-PHY | ||
| 912 | |a SSG-OLC-CHE | ||
| 912 | |a SSG-OLC-MAT | ||
| 912 | |a SSG-OLC-TGE | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_70 | ||
| 912 | |a GBV_ILN_2006 | ||
| 912 | |a GBV_ILN_2041 | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2002 |e 3 |c 09 |h 337-342 | ||
| author_variant |
a s as n p np g r gr |
|---|---|
| matchkey_str |
article:13533452:2002----::ofitfneetsenrmrsac |
| hierarchy_sort_str |
2002 |
| publishDate |
2002 |
| allfields |
10.1007/s11948-002-0053-y doi (DE-627)OLC2029167657 (DE-He213)s11948-002-0053-y-p DE-627 ger DE-627 rakwb eng 100 500 VZ 19,2 ssgn Schieppati, Arrigo verfasserin aut Conflict of interest as seen from a researcher’s perspective 2002 Text txt rdacontent ohne Hilfsmittel zu benutzen n rdamedia Band nc rdacarrier © Opragen Publications 2002 Abstract The continuous growth of the pharmaceutical industry is expected to require a considerable output of new drugs, with speedy development and approval processes. This profit-driven expansion of the drug market may broaden the already established erosion of the role of academia in favor of commercial clinical research organizations. Less and less control on the clinical trial design, its conduct and the resulting publication[s] is the likely consequence. Academic medicine and governments should find means to sustain the development of independent clinical research. conflict of interest academic research drug development and research clinical trial design Perico, Norberto aut Remuzzi, Giuseppe aut Enthalten in Science and engineering ethics Kluwer Academic Publishers, 1995 8(2002), 3 vom: Sept., Seite 337-342 (DE-627)19230397X (DE-600)1304534-9 (DE-576)051378167 1353-3452 nnns volume:8 year:2002 number:3 month:09 pages:337-342 https://doi.org/10.1007/s11948-002-0053-y lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_OLC SSG-OLC-TEC SSG-OLC-PHY SSG-OLC-CHE SSG-OLC-MAT SSG-OLC-TGE SSG-OLC-PHA SSG-OLC-DE-84 GBV_ILN_70 GBV_ILN_2006 GBV_ILN_2041 AR 8 2002 3 09 337-342 |
| spelling |
10.1007/s11948-002-0053-y doi (DE-627)OLC2029167657 (DE-He213)s11948-002-0053-y-p DE-627 ger DE-627 rakwb eng 100 500 VZ 19,2 ssgn Schieppati, Arrigo verfasserin aut Conflict of interest as seen from a researcher’s perspective 2002 Text txt rdacontent ohne Hilfsmittel zu benutzen n rdamedia Band nc rdacarrier © Opragen Publications 2002 Abstract The continuous growth of the pharmaceutical industry is expected to require a considerable output of new drugs, with speedy development and approval processes. This profit-driven expansion of the drug market may broaden the already established erosion of the role of academia in favor of commercial clinical research organizations. Less and less control on the clinical trial design, its conduct and the resulting publication[s] is the likely consequence. Academic medicine and governments should find means to sustain the development of independent clinical research. conflict of interest academic research drug development and research clinical trial design Perico, Norberto aut Remuzzi, Giuseppe aut Enthalten in Science and engineering ethics Kluwer Academic Publishers, 1995 8(2002), 3 vom: Sept., Seite 337-342 (DE-627)19230397X (DE-600)1304534-9 (DE-576)051378167 1353-3452 nnns volume:8 year:2002 number:3 month:09 pages:337-342 https://doi.org/10.1007/s11948-002-0053-y lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_OLC SSG-OLC-TEC SSG-OLC-PHY SSG-OLC-CHE SSG-OLC-MAT SSG-OLC-TGE SSG-OLC-PHA SSG-OLC-DE-84 GBV_ILN_70 GBV_ILN_2006 GBV_ILN_2041 AR 8 2002 3 09 337-342 |
| allfields_unstemmed |
10.1007/s11948-002-0053-y doi (DE-627)OLC2029167657 (DE-He213)s11948-002-0053-y-p DE-627 ger DE-627 rakwb eng 100 500 VZ 19,2 ssgn Schieppati, Arrigo verfasserin aut Conflict of interest as seen from a researcher’s perspective 2002 Text txt rdacontent ohne Hilfsmittel zu benutzen n rdamedia Band nc rdacarrier © Opragen Publications 2002 Abstract The continuous growth of the pharmaceutical industry is expected to require a considerable output of new drugs, with speedy development and approval processes. This profit-driven expansion of the drug market may broaden the already established erosion of the role of academia in favor of commercial clinical research organizations. Less and less control on the clinical trial design, its conduct and the resulting publication[s] is the likely consequence. Academic medicine and governments should find means to sustain the development of independent clinical research. conflict of interest academic research drug development and research clinical trial design Perico, Norberto aut Remuzzi, Giuseppe aut Enthalten in Science and engineering ethics Kluwer Academic Publishers, 1995 8(2002), 3 vom: Sept., Seite 337-342 (DE-627)19230397X (DE-600)1304534-9 (DE-576)051378167 1353-3452 nnns volume:8 year:2002 number:3 month:09 pages:337-342 https://doi.org/10.1007/s11948-002-0053-y lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_OLC SSG-OLC-TEC SSG-OLC-PHY SSG-OLC-CHE SSG-OLC-MAT SSG-OLC-TGE SSG-OLC-PHA SSG-OLC-DE-84 GBV_ILN_70 GBV_ILN_2006 GBV_ILN_2041 AR 8 2002 3 09 337-342 |
| allfieldsGer |
10.1007/s11948-002-0053-y doi (DE-627)OLC2029167657 (DE-He213)s11948-002-0053-y-p DE-627 ger DE-627 rakwb eng 100 500 VZ 19,2 ssgn Schieppati, Arrigo verfasserin aut Conflict of interest as seen from a researcher’s perspective 2002 Text txt rdacontent ohne Hilfsmittel zu benutzen n rdamedia Band nc rdacarrier © Opragen Publications 2002 Abstract The continuous growth of the pharmaceutical industry is expected to require a considerable output of new drugs, with speedy development and approval processes. This profit-driven expansion of the drug market may broaden the already established erosion of the role of academia in favor of commercial clinical research organizations. Less and less control on the clinical trial design, its conduct and the resulting publication[s] is the likely consequence. Academic medicine and governments should find means to sustain the development of independent clinical research. conflict of interest academic research drug development and research clinical trial design Perico, Norberto aut Remuzzi, Giuseppe aut Enthalten in Science and engineering ethics Kluwer Academic Publishers, 1995 8(2002), 3 vom: Sept., Seite 337-342 (DE-627)19230397X (DE-600)1304534-9 (DE-576)051378167 1353-3452 nnns volume:8 year:2002 number:3 month:09 pages:337-342 https://doi.org/10.1007/s11948-002-0053-y lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_OLC SSG-OLC-TEC SSG-OLC-PHY SSG-OLC-CHE SSG-OLC-MAT SSG-OLC-TGE SSG-OLC-PHA SSG-OLC-DE-84 GBV_ILN_70 GBV_ILN_2006 GBV_ILN_2041 AR 8 2002 3 09 337-342 |
| allfieldsSound |
10.1007/s11948-002-0053-y doi (DE-627)OLC2029167657 (DE-He213)s11948-002-0053-y-p DE-627 ger DE-627 rakwb eng 100 500 VZ 19,2 ssgn Schieppati, Arrigo verfasserin aut Conflict of interest as seen from a researcher’s perspective 2002 Text txt rdacontent ohne Hilfsmittel zu benutzen n rdamedia Band nc rdacarrier © Opragen Publications 2002 Abstract The continuous growth of the pharmaceutical industry is expected to require a considerable output of new drugs, with speedy development and approval processes. This profit-driven expansion of the drug market may broaden the already established erosion of the role of academia in favor of commercial clinical research organizations. Less and less control on the clinical trial design, its conduct and the resulting publication[s] is the likely consequence. Academic medicine and governments should find means to sustain the development of independent clinical research. conflict of interest academic research drug development and research clinical trial design Perico, Norberto aut Remuzzi, Giuseppe aut Enthalten in Science and engineering ethics Kluwer Academic Publishers, 1995 8(2002), 3 vom: Sept., Seite 337-342 (DE-627)19230397X (DE-600)1304534-9 (DE-576)051378167 1353-3452 nnns volume:8 year:2002 number:3 month:09 pages:337-342 https://doi.org/10.1007/s11948-002-0053-y lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_OLC SSG-OLC-TEC SSG-OLC-PHY SSG-OLC-CHE SSG-OLC-MAT SSG-OLC-TGE SSG-OLC-PHA SSG-OLC-DE-84 GBV_ILN_70 GBV_ILN_2006 GBV_ILN_2041 AR 8 2002 3 09 337-342 |
| language |
English |
| source |
Enthalten in Science and engineering ethics 8(2002), 3 vom: Sept., Seite 337-342 volume:8 year:2002 number:3 month:09 pages:337-342 |
| sourceStr |
Enthalten in Science and engineering ethics 8(2002), 3 vom: Sept., Seite 337-342 volume:8 year:2002 number:3 month:09 pages:337-342 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
conflict of interest academic research drug development and research clinical trial design |
| dewey-raw |
100 |
| isfreeaccess_bool |
false |
| container_title |
Science and engineering ethics |
| authorswithroles_txt_mv |
Schieppati, Arrigo @@aut@@ Perico, Norberto @@aut@@ Remuzzi, Giuseppe @@aut@@ |
| publishDateDaySort_date |
2002-09-01T00:00:00Z |
| hierarchy_top_id |
19230397X |
| dewey-sort |
3100 |
| id |
OLC2029167657 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">OLC2029167657</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230508184824.0</controlfield><controlfield tag="007">tu</controlfield><controlfield tag="008">200819s2002 xx ||||| 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s11948-002-0053-y</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)OLC2029167657</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-He213)s11948-002-0053-y-p</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">100</subfield><subfield code="a">500</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">19,2</subfield><subfield code="2">ssgn</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Schieppati, Arrigo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Conflict of interest as seen from a researcher’s perspective</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2002</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">ohne Hilfsmittel zu benutzen</subfield><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Band</subfield><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Opragen Publications 2002</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract The continuous growth of the pharmaceutical industry is expected to require a considerable output of new drugs, with speedy development and approval processes. This profit-driven expansion of the drug market may broaden the already established erosion of the role of academia in favor of commercial clinical research organizations. Less and less control on the clinical trial design, its conduct and the resulting publication[s] is the likely consequence. Academic medicine and governments should find means to sustain the development of independent clinical research.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">conflict of interest</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">academic research</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">drug development and research</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">clinical trial design</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Perico, Norberto</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Remuzzi, Giuseppe</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Science and engineering ethics</subfield><subfield code="d">Kluwer Academic Publishers, 1995</subfield><subfield code="g">8(2002), 3 vom: Sept., Seite 337-342</subfield><subfield code="w">(DE-627)19230397X</subfield><subfield code="w">(DE-600)1304534-9</subfield><subfield code="w">(DE-576)051378167</subfield><subfield code="x">1353-3452</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:8</subfield><subfield code="g">year:2002</subfield><subfield code="g">number:3</subfield><subfield code="g">month:09</subfield><subfield code="g">pages:337-342</subfield></datafield><datafield tag="856" ind1="4" ind2="1"><subfield code="u">https://doi.org/10.1007/s11948-002-0053-y</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_OLC</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-TEC</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-CHE</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-MAT</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-TGE</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-DE-84</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2041</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">8</subfield><subfield code="j">2002</subfield><subfield code="e">3</subfield><subfield code="c">09</subfield><subfield code="h">337-342</subfield></datafield></record></collection>
|
| author |
Schieppati, Arrigo |
| spellingShingle |
Schieppati, Arrigo ddc 100 ssgn 19,2 misc conflict of interest misc academic research misc drug development and research misc clinical trial design Conflict of interest as seen from a researcher’s perspective |
| authorStr |
Schieppati, Arrigo |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)19230397X |
| format |
Article |
| dewey-ones |
100 - Philosophy & psychology 500 - Natural sciences & mathematics |
| delete_txt_mv |
keep |
| author_role |
aut aut aut |
| collection |
OLC |
| remote_str |
false |
| illustrated |
Not Illustrated |
| issn |
1353-3452 |
| topic_title |
100 500 VZ 19,2 ssgn Conflict of interest as seen from a researcher’s perspective conflict of interest academic research drug development and research clinical trial design |
| topic |
ddc 100 ssgn 19,2 misc conflict of interest misc academic research misc drug development and research misc clinical trial design |
| topic_unstemmed |
ddc 100 ssgn 19,2 misc conflict of interest misc academic research misc drug development and research misc clinical trial design |
| topic_browse |
ddc 100 ssgn 19,2 misc conflict of interest misc academic research misc drug development and research misc clinical trial design |
| format_facet |
Aufsätze Gedruckte Aufsätze |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
nc |
| hierarchy_parent_title |
Science and engineering ethics |
| hierarchy_parent_id |
19230397X |
| dewey-tens |
100 - Philosophy 500 - Science |
| hierarchy_top_title |
Science and engineering ethics |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)19230397X (DE-600)1304534-9 (DE-576)051378167 |
| title |
Conflict of interest as seen from a researcher’s perspective |
| ctrlnum |
(DE-627)OLC2029167657 (DE-He213)s11948-002-0053-y-p |
| title_full |
Conflict of interest as seen from a researcher’s perspective |
| author_sort |
Schieppati, Arrigo |
| journal |
Science and engineering ethics |
| journalStr |
Science and engineering ethics |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
100 - Philosophy & psychology 500 - Science |
| recordtype |
marc |
| publishDateSort |
2002 |
| contenttype_str_mv |
txt |
| container_start_page |
337 |
| author_browse |
Schieppati, Arrigo Perico, Norberto Remuzzi, Giuseppe |
| container_volume |
8 |
| class |
100 500 VZ 19,2 ssgn |
| format_se |
Aufsätze |
| author-letter |
Schieppati, Arrigo |
| doi_str_mv |
10.1007/s11948-002-0053-y |
| dewey-full |
100 500 |
| title_sort |
conflict of interest as seen from a researcher’s perspective |
| title_auth |
Conflict of interest as seen from a researcher’s perspective |
| abstract |
Abstract The continuous growth of the pharmaceutical industry is expected to require a considerable output of new drugs, with speedy development and approval processes. This profit-driven expansion of the drug market may broaden the already established erosion of the role of academia in favor of commercial clinical research organizations. Less and less control on the clinical trial design, its conduct and the resulting publication[s] is the likely consequence. Academic medicine and governments should find means to sustain the development of independent clinical research. © Opragen Publications 2002 |
| abstractGer |
Abstract The continuous growth of the pharmaceutical industry is expected to require a considerable output of new drugs, with speedy development and approval processes. This profit-driven expansion of the drug market may broaden the already established erosion of the role of academia in favor of commercial clinical research organizations. Less and less control on the clinical trial design, its conduct and the resulting publication[s] is the likely consequence. Academic medicine and governments should find means to sustain the development of independent clinical research. © Opragen Publications 2002 |
| abstract_unstemmed |
Abstract The continuous growth of the pharmaceutical industry is expected to require a considerable output of new drugs, with speedy development and approval processes. This profit-driven expansion of the drug market may broaden the already established erosion of the role of academia in favor of commercial clinical research organizations. Less and less control on the clinical trial design, its conduct and the resulting publication[s] is the likely consequence. Academic medicine and governments should find means to sustain the development of independent clinical research. © Opragen Publications 2002 |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_OLC SSG-OLC-TEC SSG-OLC-PHY SSG-OLC-CHE SSG-OLC-MAT SSG-OLC-TGE SSG-OLC-PHA SSG-OLC-DE-84 GBV_ILN_70 GBV_ILN_2006 GBV_ILN_2041 |
| container_issue |
3 |
| title_short |
Conflict of interest as seen from a researcher’s perspective |
| url |
https://doi.org/10.1007/s11948-002-0053-y |
| remote_bool |
false |
| author2 |
Perico, Norberto Remuzzi, Giuseppe |
| author2Str |
Perico, Norberto Remuzzi, Giuseppe |
| ppnlink |
19230397X |
| mediatype_str_mv |
n |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/s11948-002-0053-y |
| up_date |
2024-07-03T21:56:47.369Z |
| _version_ |
1803596655359950848 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">OLC2029167657</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230508184824.0</controlfield><controlfield tag="007">tu</controlfield><controlfield tag="008">200819s2002 xx ||||| 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s11948-002-0053-y</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)OLC2029167657</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-He213)s11948-002-0053-y-p</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">100</subfield><subfield code="a">500</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">19,2</subfield><subfield code="2">ssgn</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Schieppati, Arrigo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Conflict of interest as seen from a researcher’s perspective</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2002</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">ohne Hilfsmittel zu benutzen</subfield><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Band</subfield><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Opragen Publications 2002</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract The continuous growth of the pharmaceutical industry is expected to require a considerable output of new drugs, with speedy development and approval processes. This profit-driven expansion of the drug market may broaden the already established erosion of the role of academia in favor of commercial clinical research organizations. Less and less control on the clinical trial design, its conduct and the resulting publication[s] is the likely consequence. Academic medicine and governments should find means to sustain the development of independent clinical research.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">conflict of interest</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">academic research</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">drug development and research</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">clinical trial design</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Perico, Norberto</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Remuzzi, Giuseppe</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Science and engineering ethics</subfield><subfield code="d">Kluwer Academic Publishers, 1995</subfield><subfield code="g">8(2002), 3 vom: Sept., Seite 337-342</subfield><subfield code="w">(DE-627)19230397X</subfield><subfield code="w">(DE-600)1304534-9</subfield><subfield code="w">(DE-576)051378167</subfield><subfield code="x">1353-3452</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:8</subfield><subfield code="g">year:2002</subfield><subfield code="g">number:3</subfield><subfield code="g">month:09</subfield><subfield code="g">pages:337-342</subfield></datafield><datafield tag="856" ind1="4" ind2="1"><subfield code="u">https://doi.org/10.1007/s11948-002-0053-y</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_OLC</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-TEC</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-CHE</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-MAT</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-TGE</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-DE-84</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2041</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">8</subfield><subfield code="j">2002</subfield><subfield code="e">3</subfield><subfield code="c">09</subfield><subfield code="h">337-342</subfield></datafield></record></collection>
|
| score |
7.399584 |